229 related articles for article (PubMed ID: 33619887)
1. Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy.
Kamitori T; Umeda K; Akazawa R; Iwai A; Obu S; Isobe K; Saida S; Kato I; Hiramatsu H; Taga T; Adachi S; Takita J
Pediatr Blood Cancer; 2021 May; 68(5):e28980. PubMed ID: 33619887
[No Abstract] [Full Text] [Related]
2. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
3. [CAR-T therapy for adult B-cell acute lymphoblastic leukemia].
Goto H
Rinsho Ketsueki; 2023; 64(11):1432-1439. PubMed ID: 38072431
[TBL] [Abstract][Full Text] [Related]
4. Are CAR T cells better than antibody or HCT therapy in B-ALL?
Pulsipher MA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):16-24. PubMed ID: 30504287
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C; Sartor C; Dominietto A; Zappone E; Arpinati M; Marconi G; Cristiano G; Nanni J; Parisi S; Barbato F; Paolini S; Soverini S; Terragna C; Robustelli V; Testoni N; Chirumbolo G; Curti A; Cavo M; Bonifazi F
Hematol Oncol; 2021 Oct; 39(4):580-583. PubMed ID: 33963566
[No Abstract] [Full Text] [Related]
6. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
7. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
Lu W; Lyu H; Xiao X; Bai X; Zhang M; Wang J; Pu Y; Meng J; Zhang X; Zhu H; Yuan T; Wang B; Jin X; Cao X; Wang Z; Xie T; Meng H; Stepanov AV; Gabibov AG; An Y; Sun R; Zhang Y; Maschan MA; Zhu Z; Zhang H; Zhao M
Leukemia; 2024 Jun; 38(6):1419-1422. PubMed ID: 38632315
[No Abstract] [Full Text] [Related]
9. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
10. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
11. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
[TBL] [Abstract][Full Text] [Related]
12. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
13. Loss of CD22 expression and expansion of a CD22
Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
[No Abstract] [Full Text] [Related]
15. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
18. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K; Flynn JR; Rivière I; Gönen M; Wang X; Senechal B; Curran KJ; Roshal M; Maslak PG; Geyer MB; Halton EF; Diamonte C; Davila ML; Sadelain M; Brentjens RJ; Park JH
Blood; 2021 Aug; 138(7):531-543. PubMed ID: 33851211
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
20. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
